CELESTONE SOLUSPAN 3 MG
BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 3 MG BETAMETHASONE ACETATE : 3 MG · DIN 00028096 · ORGANON CANADA INC.
Health Canada status: MARKETED
What is CELESTONE SOLUSPAN?
CELESTONE SOLUSPAN 3 MG contains BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 3 MG BETAMETHASONE ACETATE : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 00028096, held by ORGANON CANADA INC., supplied as SUSPENSION for INTRAMUSCULAR ; INTRABURSAL ; INTRA-ARTICULAR ; INTRADERMAL administration. Health Canada currently lists it as marketed, status dated 04-Aug-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CELESTONE SOLUSPAN used for?
CELESTONE® SOLUSPAN® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) is indicated in allergic, dermatologic, rheumatic, and other conditions responsive to systemic corticosteroids, including bursitis. It is also indicated in bursitis and associated inflammatory disorders of tendons such as tenosynovitis, and inflammatory disorders of muscle such as fibrosis and myositis. Furthermore, it is indicated in rheumatoid arthritis and osteoarthritis, various dermatologic conditions, and certain inflammatory and cystic disorders of the foot.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00028096 |
|---|---|
| Brand name | CELESTONE SOLUSPAN |
| Generic / active ingredient | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 3 MG BETAMETHASONE ACETATE : 3 MG |
| Manufacturer | ORGANON CANADA INC. |
| Strength | 3 MG |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR ; INTRABURSAL ; INTRA-ARTICULAR ; INTRADERMAL |
| Schedule | Prescription |
| ATC code | H02AB01 BETAMETHASONE |
| AHFS class | 68:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Aug-2022 |
| Original market date | 1965-12-31 00:00:00 |
How is it administered?
Systemic: 1-2 mL IM weekly. Local: 0.25-2.0 mL depending on joint size or condition. Intralesional: 0.2 mL/cm2 (max 1 mL weekly). Shake well. Do not give IV or SC.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
1 mL and 5 mL multiple dose vials
Contraindications
Hypersensitivity; herpes simplex of the eye; systemic fungal infections; vaccinia; cerebral malaria; idiopathic thrombocytopenia purpura (IM use); locally infected areas.
Warnings and precautions
Risk of secondary adrenocortical insufficiency; pheochromocytoma crisis; serious neurologic events with epidural use; masks signs of infection; may produce cataracts or glaucoma.
What can be used instead?
Other Canadian products sharing ATC code H02AB01 BETAMETHASONE. 1 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BETAJECT | 3 MG | SUSPENSION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02237835 |
| BETNESOL TAB 0.5MG | .5 MG | TABLET | GLAXO CANADA INC | CANCELLED POST MARKET | DIN 00036366 |
| BETNESOL TABLETS | 0.5 MG | TABLET (EFFERVESCENT) | SHIRE PHARMA CANADA ULC | CANCELLED POST MARKET | DIN 02063190 |
| CELESTONE REPETABS 1MG | 1 MG | TABLET (EXTENDED-RELEASE) | SCHERING-PLOUGH CANADA INC | CANCELLED POST MARKET | DIN 00176834 |
| CELESTONE TAB 0.5MG | 0.5 MG | TABLET | SCHERING-PLOUGH CANADA INC | CANCELLED POST MARKET | DIN 00028185 |
Who else supplies BETAMETHASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BETAMETHASONE appears in 2437 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.